Assessing carotid plaque in patients with specific blood disorders
Neutrophil-Lymphocyte Ratio and Carotid Plaque Burden in Patients With Philadelphia Negative Myeloproliferative Neoplasms and Their Relation to JAK2V617F Mutation
Sohag University · NCT05993052
This study is testing how carotid plaque affects people with certain blood disorders called myeloproliferative neoplasms to see if they have a higher risk of heart problems compared to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sohag University (other) |
| Locations | 1 site (Sohag) |
| Trial ID | NCT05993052 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates carotid plaque burden in patients diagnosed with Philadelphia negative myeloproliferative neoplasms (MPNs). Participants will undergo a comprehensive clinical assessment, including blood tests and carotid imaging using Colour Doppler ultrasonography. A control group of healthy volunteers will also be assessed to compare results based on age, sex, and common risk factors for atherosclerosis. The study aims to understand the relationship between MPNs and cardiovascular risk.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been newly diagnosed with Philadelphia negative myeloproliferative neoplasms.
Not a fit: Patients whose condition is reactive thrombocytosis or polycythemia, or those with chronic or acute myeloid leukemia, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify cardiovascular risks in patients with myeloproliferative neoplasms, leading to better management strategies.
How similar studies have performed: While there is limited data on this specific approach, studies have shown a correlation between myeloproliferative neoplasms and cardiovascular risks, suggesting potential relevance.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients aged 18 years and older who were newly diagnosed to have Philadelphia negative myeloproliferative neoplasms between September 2014 and November 2022 at Sohag university hospital, department of internal medicine, hematology unit and hematology outpatient clinic. Exclusion Criteria: * Patients were excluded if: (1) their disease of thrombocytosis or polycythemia was determined to be reactive, (2) their disease was not newly diagnosed, (3) their disease met WHO criteria for chronic or acute myeloid leukemia.
Where this trial is running
Sohag
- Faculty of Medicine — Sohag, Egypt (RECRUITING)
Study contacts
- Principal investigator: Mahmoud Gaber — Sohag University
- Study coordinator: Mahmoud Gaber, dr
- Email: mahmoudgaber@med.sohag.edu.eg
- Phone: +201007399833
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Myeloproliferative Neoplasm